These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37871326)

  • 21. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
    Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
    J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Pro.
    Ginsberg DA
    J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742453
    [No Abstract]   [Full Text] [Related]  

  • 24. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Con.
    Siegel S
    J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742452
    [No Abstract]   [Full Text] [Related]  

  • 25. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Wein AJ
    J Urol; 2017 Jun; 197(6):1524-1525. PubMed ID: 28505919
    [No Abstract]   [Full Text] [Related]  

  • 28. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Lowder J; Khandwala S; Sirls L; Spino C; Nolen TL; Wallace D; Meikle SF;
    N Engl J Med; 2012 Nov; 367(19):1803-13. PubMed ID: 23036134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
    Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
    J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Cornu JN
    Eur Urol; 2017 Jun; 71(6):988-989. PubMed ID: 28249800
    [No Abstract]   [Full Text] [Related]  

  • 34. Sacral Neuromodulation: Determining Predictors of Success.
    Morgan TN; Pace N; Mohapatra A; Ren D; Kunkel G; Tennyson L; Shepherd JP; Chermansky CJ
    Urology; 2021 Jul; 153():124-128. PubMed ID: 32619594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.
    Hendrickson WK; Xie G; Rahn DD; Amundsen CL; Hokanson JA; Bradley M; Smith AL; Sung VW; Visco AG; Luo S; Jelovsek JE
    Neurourol Urodyn; 2022 Jan; 41(1):432-447. PubMed ID: 34859485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
    Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
    J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence.
    Wang A; Rourke E; Sebesta E; Dmochowski R
    Expert Rev Med Devices; 2021 Aug; 18(8):727-732. PubMed ID: 34187274
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.